PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16082080-2	2005	We hypothesized that combining low-dose FK506 with anti-CD40 Ligand (anti-CD40L mAb) would enhance regeneration through peripheral nerve allografts while preserving immune unresponsiveness.	Tacrolimus	40-45	CD40 ligand	Mus musculus	74-79	
16082080-5	2005	RESULTS: Animals receiving low-dose FK506 with anti-CD40L mAb exhibited robust nerve regeneration comparable to the isograft and high-dose FK506 allograft groups.	Tacrolimus	36-41	CD40 ligand	Mus musculus	52-57	
16082080-6	2005	Nerve density was significantly increased in the low-dose FK506 with anti-CD40L mAb group compared to animals receiving anti-CD40L mAb alone (p < 0.05).	Tacrolimus	58-63	CD40 ligand	Mus musculus	74-79	
16082080-10	2005	CONCLUSION: When combined with anti-CD40L mAb, low-dose FK506 enhances nerve regeneration without disrupting immune unresponsiveness.	Tacrolimus	56-61	CD40 ligand	Mus musculus	36-41